TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07670858: Study of Intralesional FLD-103 in Subjects With Basal Cell Carcinoma (BCC)

Sponsor: Feldan Therapeutics · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 48 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$1,193,808

Rescue Site Savings

+$785,400

Unlock Full NCT07670858 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07670858 Rescue Dossier →